• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Janus Kinase Inhibitor (JAKs)
    2 Drugs classified under this drug class


    All the Drug Class Drugs

    Olumiant
    Eli Lilly
    RX
    partial basket chart
    Olumiant

    Janus Kinase Inhibitor (JAKs). Baricitinib 2 mg, 4 mg.
    F.C. TABS.: 28. 4 mg ×1/d. A dose of 2 mg×1/d. is approp. for pts. such as those aged ≥ 75 yrs. and may be approp. for pts. with a history of chron. or recur. infect. A dose of 2 mg×1/d may also be consid. for pts. who have achieved sustain. control of dis. active. with 4 mg×1/d and are eligible for dose tapering. Tmt. should not be initiat. in pts. with an absolute lymphocyte count (ALC) less than 0.5 x 109 cells/L, an absolute neutrophil count (ANC) less than 1 x 109 cells/L, or who have a haemoglobin value less than 8 g/dL. Tmt. may be initiat. once values have improv. above these limits. See lit.
    Tmt. of moder.- severe active RA in adult pts. who have responded inadequate. to, or who are intolerant to one or more dis.-modif. anti-rheum. drugs. May be used as monother. or in comb. with methotrexate.
    C/I: Hypersens. Preg.

    Xeljanz 5 mg
    Pfizer
    RX
    partial basket chart
    Xeljanz 5 mg

    Janus Kinase Inhibitor (JAKs). Tofacitinib 5 mg.
    F.C. TAB: 28, 60, 180. Rheum. Arthrit: The drug may be used as monotherapy/in combin. with methotrexate or other non-biologic dis. modif. antirheum. drugs (DMARDs): 5 mg×2/d dly. oral. with/without food.
    Psoriat. Arthrit: 5 mg×2/d dly. oral. with/without food, used in comb. with non-biologic DMARDs. The efficacy of Tofacitinib as a monother. has not been studied in psoriat. arthritis.
    UC: 10 mg×2/d for at least 8 wks.; follow. by 5/10 mg×2/d, depend. on therapeut. response. Use the lowest effective dose to maint. response. Discont. Tofacitinib after 16 wks. of tmt. with 10 mg×2/d, if adequate therap. benefit is not achieved See lit.
    Rheum. Arthrit: Indic. for the tmt. of adult. pts. with moderat. to sev. active RA who have had an inadeq. response or intolerance to methotrexate. It may be used as mono-ther. or in comb. with methotrexate/other non-biolog. DMARDs.
    Limitations of Use: Use of Tofacitinib in comb. with biologic DMARDs or with potent immune-suppressant. such as azathioprine & cyclosporine is not recomm.
    Psoriat. Arthrit.: Indicated for the tmt. of adult pts. with active psoriat. arthrit. who have had an inadeq. response or intoleran. to methotrexate or other DMARDs.
    Limitations of Use: Use of Tofacitinib in comb. with biologic DMARDs or with potent immune-suppressant. such as azathioprine & cyclosporine is not recomm.
    Ulcerat. colitis: Tmt. of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intoler. to either convent. ther. or a biologic agent.
    Limitations of Use: Use of Tofacitinib in comb. with biology. therap. for UC or with potent immunosuppress. such as azathioprine and cyclosporine is not recomm.
    C/I: Hypersens.

    CLOSE